GNCA News and Press, Genocea Biosciences Inc. From 04/29/21

Genocea Biosciences, Inc. (GNCA) Q1 2021 Results Conference Call April 29, 2021 08:30 AM ET Company Participants Dan Ferry - Investor Relations Chip Clark - President and Chief Executive Officer Diantha Duvall - Chief Financial Officer Tom Davis - Chief Medical Officer Jessica Flechtner - Chi...

GEN-011 and GEN-009 immuno-oncology programs continue to advance Research on Inhibigens ™ and SARS-CoV-2 continues to progress Conference call today at 8:30 a.m. E.T. CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Genocea Biosci...

CAMBRIDGE, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its first quarter 2021 financial results and corporate update conference call and live audio webcas...

Pro-tumor effects detected as early as four days after Inhibigen administration Insights into Inhibigen biology may yield new therapeutic targets to address immunotherapy resistance CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:...

CAMBRIDGE, Mass., April 06, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, President and Chief Executive Officer, will present a corporate overview at ...

Innovation, R&D and an aging population are long-term secular trends that will provide a tailwind to the biotechnology sector. The Insurgent AI Deep Innovation Model uses Deep Learning and secular tailwinds to generate alpha. Evaluating investment strategies is challenging, es...

Immatics is a very early-stage biotech company with most assets still in the pre-clinical phase. They have a proprietary oncology platform that generates T cell targets against Cancer-Testis Antigens. Despite being exceptionally early in development, Immatics already has establish...

CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, President and Chief Executive Officer, will present a corporate overview at ...

Genocea Biosciences, Inc. (GNCA) Q4 2020 Earnings Conference Call February 11, 2021, 08:30 AM ET Company Participants Dan Ferry - IR, LifeSci Advisors Chip Clark - President and CEO Diantha Duvall - CFO Tom Davis - Chief Medical Officer Jess Flechtner - Chief Scientific Officer Conference Cal...

Genocea Biosciences (GNCA): Q4 GAAP EPS of -$0.18 beats by $0.03.As of December 31, 2020, cash and cash equivalents were $79.8 million compared to $40.1 million as of December 31, 2019.Press Release For further details see: Genocea Biosciences EPS beats by $0.03